Malaria among remains the most significant infectious disease facing U.S. Service Members deployed around the world. Infection with malaria is responsible for an estimated 5,300-21,000 lost work hours and $1.12-4.37 million per year in evacuation and medical care costs despite existing countermeasures like chemoprophylactic drugs, permethrin-impregnated uniforms, bed nets, and DEET. These infections are largely driven by poor adherence to personal protective measures, chemoprophylaxis, and rising regional drug resistance.
A safe, durable, and efficacious malaria vaccine will eliminate the burden of compliance and associated side effects of daily or weekly chemoprophylaxis, overcome regional drug resistance to currently available antimalarials, and provide an alternative to individuals with G6PD deficiency. Protection against malaria infection improves unit readiness and the likeliness of mission success.
MVB is an integrated, broad, translational enterprise spanning discovery science to field efficacy trials. Our mission is to develop new vaccines and other products to reliably prevent malaria infection in military personnel by maintaining robust, expert competency in basic and applied research areas in order to transition candidate products to advanced clinical testing in endemic areas.